Primary Myelofibrosis (DIPSS-Plus stratified) · line 1 · Ruxolitinib (PMF — symptomatic splenomegaly / constitutional symptoms)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-RUX-PMF`

ID	`IND-PMF-1L-RUXOLITINIB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-PMF`
Sources	`SRC-COMFORT-I-VERSTOVSEK-2012` `SRC-DIPSS-PLUS-GANGAT-2011` `SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025`

Notes

AGGRESSIVE track for PMF 1L symptomatic / higher-risk. STUB — requires clinical co-lead signoff.

Used By

Algorithms

ALGO-PMF-1L - ALGO-PMF-1L